These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22509668)

  • 1. [Promising on advanced cancer, several new drugs coming].
    Widmark A; Karlsson CT
    Lakartidningen; 2012 Feb 22-28; 109(8):416-9. PubMed ID: 22509668
    [No Abstract]   [Full Text] [Related]  

  • 2. New agents in the arsenal to fight castrate-resistant prostate cancer.
    Ezzell EE; Chang KS; George BJ
    Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Castration refractory prostate cancer: cinderella finally comes to the ball.
    Chowdhury S; Harper P; Powles T
    Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
    [No Abstract]   [Full Text] [Related]  

  • 5. Abiraterone and increased survival in metastatic prostate cancer.
    Sonpavde G
    N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
    [No Abstract]   [Full Text] [Related]  

  • 6. New prostate cancer drugs hold promise.
    Cancer; 2013 Jan; 119(2):247-8. PubMed ID: 23292897
    [No Abstract]   [Full Text] [Related]  

  • 7. Advanced clinical states in prostate cancer.
    Cheng HH; Lin DW; Yu EY
    Urol Clin North Am; 2012 Nov; 39(4):561-71. PubMed ID: 23084531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatment options for castration-resistant prostate cancer.
    Simondsen K; Kolesar J
    Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.
    Vasani D; Josephson DY; Carmichael C; Sartor O; Pal SK
    Maturitas; 2011 Oct; 70(2):194-6. PubMed ID: 21831545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new era for castrate resistant prostate cancer: a treatment review and update.
    Fong MK; Hare R; Jarkowski A
    J Oncol Pharm Pract; 2012 Sep; 18(3):343-54. PubMed ID: 22343966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Strategy in advanced castration-resistant prostate cancer].
    Gross-Goupil M; Roca S; Pasticier G; Ravaud A
    Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abiraterone and castration-resistant prostate cancer.
    Burki TK
    Lancet Oncol; 2013 Feb; 14(2):e48. PubMed ID: 23487849
    [No Abstract]   [Full Text] [Related]  

  • 14. [2017 ASCO: Complete androgen blockade strikes back].
    Penel N
    Bull Cancer; 2017; 104(7-8):599-601. PubMed ID: 28688745
    [No Abstract]   [Full Text] [Related]  

  • 15. New treatment options for castrate-resistant prostate cancer: a urology perspective.
    Gomella LG; Gelpi F; Kelly WK
    Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
    Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
    [No Abstract]   [Full Text] [Related]  

  • 17. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
    D'Amico AV
    J Clin Oncol; 2014 Feb; 32(4):362-4. PubMed ID: 24344221
    [No Abstract]   [Full Text] [Related]  

  • 18. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Tanimoto T; Hori A; Kami M
    N Engl J Med; 2010 Nov; 363(20):1966; author reply 1967-8. PubMed ID: 21067392
    [No Abstract]   [Full Text] [Related]  

  • 19. Managing advanced prostate cancer: the rapidly changing treatment landscape.
    Dreicer R
    Am J Manag Care; 2014 Dec; 20(12 Suppl):S282-9. PubMed ID: 25734964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.
    Armstrong AJ
    Oncology (Williston Park); 2014 Oct; 28(10):881, 883. PubMed ID: 25323615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.